Announcements Trials
Browse Landscape

Status

Unknown 4Withdrawn 1Terminated 1Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Diagnostic Imaging × Clear all
NCT03057743 2021-11-18

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Terminated
4 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡